Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
search results for:
merck
Search
Exclusive: Kennedy picks for vaccine advisory board were paid experts against Merck in civil cases
6 days ago
R&D
Pharma
FDA adds biomarker limits to stomach, esophageal cancer labels for Merck's Keytruda and BMS' Opdivo
Last week
Pharma
FDA+
Updated: Merck wins FDA approval for RSV antibody drug, making a hot market more competitive
Last week
R&D
Pharma
Merck says its oral PCSK9 inhibitor ‘significantly’ cut cholesterol in two Phase 3 trials
Last week
R&D
Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer
3 weeks ago
R&D
Pharma
Eisai, Merck stave off generic competition to blockbuster cancer drug Lenvima
3 weeks ago
Pharma
Law
Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss
3 weeks ago
R&D
Pharma
Updated: Merck KGaA continues US tariff surcharge but at a 'decreased' rate
Last month
China
Pharma
Merck plans to bring Keytruda production to the US with $1B biologics factory
Last month
Manufacturing
Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B
Last month
Deals
Pharma
Merck KGaA closes in on SpringWorks deal at $3.5B price point
Last month
Deals
Pharma
Merck is ‘well-positioned’ on Keytruda ahead of threatened pharma tariffs, CEO says
Last month
Pharma
Halozyme sues Merck, alleging injectable Keytruda will infringe its patents
Last month
Pharma
Law
Merck’s Gardasil sales sink further amid China market pressure
Last month
China
Pharma
Merck explores potential of oral peptides in deal with Austrian biotech
2 months ago
Deals
R&D
Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15
2 months ago
Bioregnum
R&D
Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy
2 months ago
R&D
Pharma
AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival
2 months ago
R&D
1
2
3
4
Next page
Last page
latest
Most read
Gilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot
20 hours ago
Pharma
FDA+
Grail shares jump on study results for cancer test
20 hours ago
Pharma
Diagnostics
Compounders lose case over semaglutide shortage
20 hours ago
Pharma
Health Tech
Zealand study shows higher GLP-1/GLP-2 doses may lead to greater weight loss
21 hours ago
R&D
see latest stream
